PD-L1 has been shown to activate the mammalian target of the rapamycin complex 1 (mTORC1) pathway, which drives tumor cell proliferation and enhances metabolic efficiency, thus promoting glucose uptake and glycolysis, which are essential for sustaining the high proliferative rate of cancer cells [25,26]. Here, CD274 is linked to cancer.